drugset / Trial / NCT07163793

Pilot Study of Reduced Venetoclax Exposure

NCT07163793

Phase 2 Recruiting 41 enrolled Northwell Health
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Pilot Study of Reduced Venetoclax Exposure

Timeline

Start
2024-10-07
Primary completion
2026-10
Completion
2028-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Venetoclax Small molecule 400 mg
Comparator Azacitidine Other / unclassified
Comparator Decitabine Small molecule